乙酰半胱氨酸胶囊联合福多司坦片致多形红斑型药疹1例分析

doi:10.19803/j.1672-8629.2022.02.23

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (2): 217-218.
DOI: 10.19803/j.1672-8629.2022.02.23

乙酰半胱氨酸胶囊联合福多司坦片致多形红斑型药疹1例分析

王新, 张捷, 张明, 张楠, 艾超^*

清华大学附属北京清华长庚医院药学部,清华大学临床医学院,北京 102218

收稿日期:2020-06-10 出版日期:2022-02-15 发布日期:2022-02-15
通讯作者: ^*艾超,男,副主任药师,医院药事管理与精准化药学。E-mail：aichao@btch.edu.cn
作者简介:王新,女,本科,药师,药事管理与临床药学。

One case of erythema multiforme drug eruption induced by acetylcysteine capsule combined with fudosteine tablets

WANG Xin, ZHANG Jie, ZHANG Ming, ZHANG Nan, AI Chao^*

Department of Pharmacy, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China

Received:2020-06-10 Online:2022-02-15 Published:2022-02-15

摘要/Abstract

摘要： 目的探讨乙酰半胱氨酸胶囊联合福多司坦片致多形红斑型药疹的可能机制。方法分析2020年2月发生的1例由口服乙酰半胱氨酸胶囊联合福多司坦片致多形红斑型药疹的病例资料并进行文献分析。结果患者在服用乙酰半胱氨酸胶囊和福多司坦片3 d后,足部出现水疱,随后皮肤溃破,并出现表皮剥脱,后手部出现相同症状,考虑为药物引起的多形红斑型药疹,停用乙酰半胱氨酸胶囊和福多司坦片后,患者皮肤症状逐渐好转。结论乙酰半胱氨酸胶囊与福多司坦片联合应用可能会引起多型红斑型药疹,在临床应用过程中应加强对药品不良反应的关注。

关键词: 乙酰半胱氨酸胶囊, 福多司坦片, 多形红斑型药疹, 用药安全, 药品不良反应

Abstract: Objective To explore the possible mechanism by which acetylcysteine capsules combined with fordostetin tablets cause erythema multiforme drug eruption. Methods One case of erythema multiforme drug eruption caused by oral acetylcysteine capsules combined with fordosteine tablets in February 2020 and rdlared Literature were analyzed. Results Three days after taking acetylcysteine capsules and fudosteine tablets, the patient had blisters on feet, followed by skin rupture and epidermal peeling. The same symptoms were then observed in hands, which was believed to be erythema multiform drug eruption caused by drugs. After the discontinuation of acetylcysteine capsules and fudosteine tablets, the patient's skin symptoms gradually improved. Conclusion The combined application of acetylcysteine capsules and fudosteine tablets may cause erythema multiform drug eruption, so clinicians should be alert to related adverse drug reactions.

Key words: acetylcysteine capsule, fudosteine tablets, erythema multiform drug eruption, medication safety, adverse drug reaction

中图分类号:

R969.3R994.11

王新, 张捷, 张明, 张楠, 艾超. 乙酰半胱氨酸胶囊联合福多司坦片致多形红斑型药疹1例分析[J]. 中国药物警戒, 2022, 19(2): 217-218.

WANG Xin, ZHANG Jie, ZHANG Ming, ZHANG Nan, AI Chao. One case of erythema multiforme drug eruption induced by acetylcysteine capsule combined with fudosteine tablets[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 217-218.

参考文献

[1] ROGERS DF.Mucoactive agents for airway mucus hypersecretory diseases[J]. Respir Care, 2007, 52(9): 1176-1197.
[2] DECHANT KL, NOBLE S.Erdosteine[J]. Drugs, 1996, 52(6): 875-882.
[3] ZHANG MY, YIN H, LI RX, et al.Research progress of N-acetyl-cysteine antioxidation in the treatment of chronic obstructive pulmonary disease[J]. Journal of Hebei Medical University(河北医科大学学报), 2019, 40(8): 980-984.
[4] MIAO LH, DONG JY, CAI HR, et al.Application of N-acetylcysteine in acute exacerbation of chronic obstructive pulmonary disease in the elderly[J]. Clin J Med Offic(临床军医杂志), 2018, 46(7): 800-802.
[5] WEN LX, CHEN SJ, HE JL.Meta analysis of the effect of fudosteine versus ambroxol on expectorant[J]. Chin J Mod Drug Appl(中国现代药物应用), 2018, 12(6): 3-5.
[6] XU JP.Oral acetylcysteine tablets for clinical analysis of inpatients with bronchiectasis[J]. China & Foreign Medical Treatment(中外医疗), 2018, 37(23): 98-99.
[7] GE ML.The types of drug eruption, diagnosis and treatment[J]. Chinese Journal of Pharamacovigilance(中国药物警戒), 2006, 3(1): 43-46.
[8] LI SQ, ZENG ZL.Progression of diagnosis and treatment of severe drug eruption[J]. Herald of Medicine(医药导报), 2008, 27(12): 1427-1430.
[9] SHAN AL, ZHAO GY, QIAN SY.Investigation and analysis the adverse drug reaction of levofloxacin on domestic and foreign case report[J]. Chin J Clin Pharmacol(中国临床药理学杂志), 2012, 28(3): 212-217.
[10] HU MY.400 cases of adverse drug reactions induced by piperacillin sodium and tazobactam sodium[J]. Evaluation and Analysis of Drug-Use in Hospitals of China(中国医院用药评价与分析), 2018, 18(6): 850-852.
[11] WEI S, XIE YM.Interpretation of cause-and-effect judgment principles and evaluation methods for adverse reactions at home and abroad[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2012, 37(18): 2744-2747.
[12] ZHAO YH.14 cases of adverse drug reaction induced by acetylcy-steine injection[J]. Herald of Medicine(医药导报), 2019, 38(9): 1233-1235.
[13] TANG J, ZHU LQ, YU GS, et al.A case of tracheal spasm induced by acetylcysteine membrane tablet[J]. Chinese Journal of Pharamacovigilance(中国药物警戒), 2010, 7(8): 506.
[14] WANG XL, LI YQ, SONG YQ, ET AL.One case of angioedema induced by acetylcysteine injection[J]. Chinese Journal of Pharam-acovigilance(中国药物警戒), 2020, 17(5): 305-307.
[15] APPELBOAM AV, DARGAN PI, KNIGHTON J.Fatal anaphylactoid reaction to N-acetylcysteine: caution in patients with asthma[J]. Emerg Med J, 2002, 19(6): 594-595.
[16] TIAN Y, LI Y.Analysis of clinical efficacy and safety of fudosteine capsule in the clearance of sputum[J]. Journal of Clinical Pulmonary Medicine(临床肺科杂志), 2013, 18(7): 1252-1254.
[17] CHEN JF, LIU M, ZHANG XC.One case of nervous system damage caused by fudosteine[J]. Evaluation and Analysis of Drug-Use in Hospitals of China(中国医院用药评价与分析), 2015, 15(11): 1564.
[18] SANDILANDS EA, BATEMAN DN.Adverse reactions associated with acetylcysteine[J]. Clin Toxicol (Phila), 2009, 47(2): 81-88.

乙酰半胱氨酸胶囊联合福多司坦片致多形红斑型药疹1例分析

One case of erythema multiforme drug eruption induced by acetylcysteine capsule combined with fudosteine tablets

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.